US Patent:
20210403557, Dec 30, 2021
Inventors:
Mingmei CAI - Boston MA, US
Elliot K. CHARTASH - Rahway NJ, US
Jane Anne HEALY - Rahway NJ, US
Mallika LALA - Rahway NJ, US
Tommy Ruosi LI - Edison NJ, US
Kapil MAYAWALA - Rahway NJ, US
Raluca Andreia PREDOIU - Kenilworth NJ, US
Sybil M.G. WILLIAMS - Boston MA, US
Zhen ZENG - Westfield NJ, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07K 16/28
A61P 35/00
Abstract:
The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.